帕洛诺司琼预防GP方案治疗非小细胞肺癌引起恶心、呕吐的疗效分析

Clinical observation of palonosetron combined with dexamethasone preventing chemotherapy induced nausea and vomiting in NSCLC patients receiving gemcitabine plus cisplatin regimen

目的探讨帕洛诺司琼联合地塞米松以及帕洛诺司琼单用预防非小细胞肺癌吉西他滨加顺铂(GP)化疗所致相关性恶心呕吐(CINV)效果差异。方法采用随机对照原则将收集确诊的60例非小细胞肺癌患者分为治疗组30例和对照组30例,其中对照组在GP化疗基础上给予帕洛诺司琼抗吐,治疗组在对照组基础上化疗时同步给予地塞米松。记录患者恶心呕吐及不良反应状况,分析两组间CINV控制率间差异。结果治疗组和对照组预防急性呕吐有效率(86.67%vs 63.33%)和预防延迟性呕吐有效率(90.00%vs 60.00%)均存在显著差异(P均小于0.05);治疗组和对照组患者恶心控制有效率分别为80.00%和43.33%,差异有统计学意义(P<0.05);治疗组和对照组不良反应发生率间的差异均无统计学意义。结论帕洛诺司琼联合地塞米松能有效预防GP方案治疗非小细胞肺癌所致急性呕吐、延迟性呕吐及恶心,且不良反应轻微,联合疗法控制CINV有效率明显优于单用方案。

Objective To investigate the antiemetic efficacy and safety of palonosetron plus dexamethasone on preventing nausea and vomiting induced by chemotherapy with gemcitabine plus cisplatin regimen（GP） in non-small-cell lung cancer（NSCLC）patients. Methods 60 cases of NSCLC patients receiving GP chemotherapy were randomly assigned to 2 groups,30 cases in treatment group were given palonosetron plus dexamethasone regimen,another group with palonosetron. The situation of nausea,vomiting and adverse reactions was observed and recorded. Results The controlled rates to acute and delayed vomiting in the treatment group were significantly higher than those in control group（86.67% vs 63.33%;90.00% vs 60.00%,P〈0.05）. Also,there was a difference in controlled rates to nausea between treatment group and the contron（80.00% vs 43.33%,P〈0.05）. The adverse reactions were all mild and generally well tolerated in patients of two groups. Conclusion Palonosetron plus dexamethasone is safe and effective in preventing chemotherapy induced nausea and vomiting in NSCLC patients receiving gemcitabine plus cisplatin regimen.